Company news
Vitasora Health Limited (ASX:VHL) news
Vitasora Health Limited news releases on 6ix. Latest, Mar 26, 2020: Placement completed
Press releases — page 3
Placement completed
March 26, 2020
Placement - investor presentation
March 16, 2020
First batch of wheezos delivered
March 5, 2020
FDA update
January 30, 2020
FDA submission to be lodged
January 29, 2020
Cancellation of shares and options
December 19, 2019
SaaS model & First 500 devices
December 12, 2019
CE Mark, manufacturer & clinical study agreement
December 9, 2019
Chairmans Address to Shareholders
November 25, 2019
Director and CEO Appointment
November 24, 2019
Change of Chairman
November 14, 2019
Update regarding departure of CEO
October 29, 2019
CEO leaving
October 9, 2019
Medical trial in India update
September 20, 2019
Placement of ordinary shares
July 29, 2019
Suspension from Official Quotation
July 28, 2019
India Joint Venture Agreement
May 2, 2019
Appendix 4D and Interim Financial Report - December 2018
February 26, 2019
Completion Of Share Purchase Plan Offer
February 4, 2019
Respiris Share Purchase Plan
January 6, 2019
$3.2M Share Placement
December 18, 2018
Trading halt
December 13, 2018
Appendix 4C and R&D Incentive Announcement
October 29, 2018
RESPIRI APPOINTS MANUFACTURING PARTNER
September 6, 2018
Appendix 4E and Audited FY2018 Financial Report
August 31, 2018
CEO Operational Review
July 30, 2018
Significant Milestone Progress
May 30, 2018
Respiri Limited - Functional Prototype Completed
April 19, 2018
RESPIRI LIMITED $3.0m SHARE PLACEMENT
April 10, 2018
Appendix 4D and Interim Financial Report - December 2017
February 26, 2018
CEO Update and Reaffirmation of 2018 Plans and Milestones
January 29, 2018
Respiri Appoints New Chief Executive Officer
October 15, 2017
Response to ASX Price Query
October 10, 2017
Breath Sensor Partnership with Grey Innovation Commenced
September 12, 2017
Appendix 4E & Annual Financial Report (30 June 2017)
August 30, 2017
Commencing the last step to commercialisation
July 27, 2017
Respiri & China
May 30, 2017
Appendix 4C - Quarterly
April 27, 2017
European CE Mark Approval Received
April 11, 2017
Text and App Messaging for Better Asthma Care
February 27, 2017
Respiri Appendix 4D and Interim Financial Report - Dec 2016
February 26, 2017
Dec 16 Appendix 4C - Respiri
January 31, 2017
RESPIRI COMPLETES CORE SOFTWARE PLATFORM
January 30, 2017
Overnight Monitoring Product Accelerated
December 14, 2016
UK Offers Scope for Respiri to Develop Key Partnerships
November 8, 2016
S&P DJ Indices Announces March Quarterly Rebalance
November 7, 2016
Appendix 4C - First Quarter Cash Report - FY2017
October 26, 2016
Appendix 4E & Annual Financial Report (30 June 2016)
August 31, 2016
Appendix 4C - Fourth Quarter Cash Report - FY2016
July 29, 2016
Independent Study Confirms AirSonea Detects Asthma Wheezing
July 25, 2016